EGFR and non-small cell lung carcinoma: Though adding cytotoxic chemotherapy to first-line gefitinib in non-selected EGFR mutant NSCLC resulted in improved survival [55], further predictive values of ctDNA with combination treatment will be quantified in ongoing trials [56].